Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical ...

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck is particularly exposed to the tariff threat, as much of its production of Keytruda takes place at facilities in ...

Merck has initiated construction of a $1 billion, 470,000-square-foot biologics center of excellence in Wilmington, Delaware.

It will build a Wilmington, Delaware facility dedicated to making its cancer drug, Keytruda, for U.S. patients.

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

Merck starts construction on a $1B biologics facility in Wilmington, Del., expected to create 500+ jobs and support Keytruda production.

The American Association for Cancer Research’s annual conference featured updates from several companies on key candidates ...